true

Prof Webster K. Cavenee, Ph.D

Director
Ludwig Institute for Cancer Research, San Diego

Professor of Medicine and Cell & Molecular Medicine Cancer Biology Program
University of California San Diego

Watch Webster's video
close

Prof Webster K. Cavenee, Ph.D

Director
Ludwig Institute for Cancer Research, San Diego

Professor of Medicine and Cell & Molecular Medicine Cancer Biology Program
University of California San Diego

Watch Webster's video

Dr Cavenee is Director of the Ludwig Institute for Cancer Research, San Diego and Distinguished Professor at the University of California, San Diego. His work on the genetic basis of cancer predisposition and progression comprises more than 300 publications and has been recognised with more than 80 honours and awards.

Dr. Cavenee completed his graduate and postdoctoral training in cell biology, biochemistry and human genetics. He received his Ph.D. with honours in 1977 from the University of Kansas Medical School and then did postdoctoral work at the Jackson Laboratory, the Massachusetts Institute of Technology and the Howard Hughes Medical Institute at the University of Utah. He has held faculty positions at the University of Cincinnati and McGill University (where he was the Founding Director of the Ludwig Institute for Cancer Research, Montreal Branch).

From 1991-2015 he was Founding Director of the Ludwig Institute for Cancer Research, San Diego Branch and Distinguished Professor of Medicine at the University of California at San Diego. Between 2015-2020, he was Director, Strategic Alliances-CNS of Ludwig Cancer Research with global responsibilities.

He is now Director Emeritus of the Ludwig Institute for Cancer Research and Distinguished Professor Emeritus at the University of California at San Diego. Dr. Cavenee’s most recognised accomplishments are in the genetic basis of cancer predisposition, tumour progression, oncogenic cellular signalling and the use of genetic approaches for cancer diagnosis and prognosis.

His efforts led to an international alliance against brain cancer and he now serves on the Board of Directors of the resultant Global Coalition for Adaptive Research, a 501(c)3 organization that is the engine for the GBM AGILE adaptive global clinical trial as well as other adaptive trials in other diseases.

He also has served on many NIH review and advisory panels including the Boards of Scientific Counselors of the National Cancer Institute and the National Institute of Environmental Health Sciences, and advisory boards for several NIH Cancer Center Support, SPORE and PO1 grants (government support grants, USA), as well those of several private foundations and international institutions.

He has served on the Boards of Directors or Scientific Advisory Boards of a dozen companies in four countries. He has been President of the American Association for Cancer Research.

Dr. Cavenee is an elected member/fellow of the US National Academy of Sciences, the US National Academy of Medicine, the Leopoldina German Academy of Science, the Chinese Academy of Engineering, the AACR Academy, the International Union Against Cancer, the American Society for Clinical Investigation and the American Academy of Microbiology.

He has published nearly 400 scientific papers and received more than 125 honours, most notably the Charles S. Mott Prize of the General Motors Cancer Research Foundation, the Albert Szent-Gyorgyi Award from the National Foundation for Cancer Research, the Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research from the American Association for Cancer Research, the Feldman Founder’s Award from the National Brain Tumour Society, the Lifetime Achievement Award from the Society for Neuro-Oncology, the Helen Keller Award from the Association for Research in Vision and Ophthalmology, the Friendship Award from the People’s Republic of China and Fellowship in the German Helmholtz Association.

quote-icon

"It is an honour to be able to help Cure Brain Cancer Foundation in its efforts to discover the causes and therapies for brain cancer as they make life better for those who have developed the disease. Together we can defeat this scourge."

Prof Webster K. Cavenee, Ph.D
Read more

Prof Timothy Cloughesy, Ph.D, MD

Professor of Neurology and Molecular and Medical Pharmacology
David Geffen School of Medicine, University of California, Los Angeles (UCLA)

Director of UCLA Neuro-Oncology Program and Co-director
UCLA Brain Tumour Center

Watch Timothy's video
close

Prof Timothy Cloughesy, Ph.D, MD

Professor of Neurology and Molecular and Medical Pharmacology
David Geffen School of Medicine, University of California, Los Angeles (UCLA)

Director of UCLA Neuro-Oncology Program and Co-director
UCLA Brain Tumour Center

Director
Henry Singleton Brain Cancer Research Program

Watch Timothy's video

Prof Cloughesy is a Professor of Neurology at the David Geffen School of Medicine at UCLA. Dr. Cloughesy’s research includes therapeutic, imaging, translational and basic investigations. His experience with clinical trials includes therapeutic approaches such as small molecule inhibitors, antibodies, antibody drug conjugates, chemotherapies, vaccines, viral gene transfer, and immune check point therapies.

Dr. Cloughesy received his B.A. degree with honours from the University of California, Santa Barbara, and his M.D. from Tulane University. He completed his neurology residency and fellowships in clinical neurophysiology at University of California, Los Angeles. Dr. Cloughesy is board certified in neurology and clinical neurophysiology and has the UCNS Neuro-Oncology Certification.

He is the director of the Neuro-Oncology Program at UCLA and the Director of the Henry Singleton Brain Cancer Research Program. He is a member of the Brain Research Institute and Jonsson Comprehensive Cancer Center at UCLA. He has experience in leadership roles for first in human and more traditional Phase I through Phase III studies.

His focus on clinical trials in brain cancer involves novel clinical trial design, incorporation of biomarkers and development of new biomarkers. He provided principal leadership for the accelerated approval and the conversion to full approval of the drug bevacizumab for recurrent glioblastoma. He has developed a brain cancer bioinformatics database which combines clinical outcomes, imaging, and molecular analysis to foster and enhance translational research.

Dr Cloughesy has authored over 380 peer-reviewed articles on brain cancer. He receives funding from NIH (major government funding body, USA), NBTS, IVY Foundation and other private foundations, including a recent Brain Cancer SPORE at UCLA where he functions as co-principal investigator. He is the global principal investigator for GBM AGILE which was created as a master protocol utilising an adaptive Bayesian approach for late stage global glioblastoma development.

Read more

Dr Alan Olivero, PhD

President
Olivero Consulting Inc. San Francisco

Former Head of Research Operations
Genentech

Watch Alan's video
close

Dr Alan Olivero, PhD

President
Olivero Consulting Inc. San Francisco

Former Head of Research Operations
Genentech

Watch Alan's video

Dr. Alan Olivero is a consultant specialising in drug discovery and development. He is currently president of Olivero Consulting Inc. In 2018 he retired from Genentech, Inc., where he worked for 25 years, rising to the level of Senior Director of Discovery Chemistry and Head of Research Operations. In that role he oversaw much of the medicinal chemistry conducted at Genentech, leading research and drug development teams.

Dr. Olivero’s research has contributed to programs in immunology, cardiovascular and neuro-degenerative disease, as well as his focus area of oncology.

Dr Alan Olivero has a B.S degree in Chemistry from Stanford University, completed postgraduate work at the Swiss Federal Institute of Technology in Zurich (ETH), and received his Ph.D. in Organic Chemistry from Stanford University in 1988.

During his time with Genentech he led research teams to 8 clinical candidates, and has started up, contributed to, or overseen several other programs that brought novel oncology agents to the clinic. Many of these novel therapeutics are now in various stages of clinical development. Dr. Olivero is recognised as an engaging scientific collaborator and has served on the joint steering committee for multiple Genentech collaborations over the years. In 2011 he was asked to serve as Head of Research Operations at Genentech.

Scientifically, Dr. Olivero is an expert in intracellular signalling pathways in cancer. He was the Genentech research leader of the PI3K franchise that delivered various novel PI3K pathway inhibitors to the clinic. He led the research team and is a coinventor of the brain penetrant PI3K/mTor inhibitor (which regulates cell growth, motility, survival, metabolism, and angiogenesis/blood vessel formation in cancer) GDC-0084 (paxalisib) - a small molecule currently in phase III clinical trials for high grade glioma. In addition to leading the research team that discovered GDC-0084, he also led the Genentech GDC-0084 Early Development Team that brought GDC-0084 into the clinic for high-grade gliomas.

Dr. Olivero is passionate about finding new ways to tackle brain cancer. He was an invited speaker at the National Brain Tumour Society Scientific Summit in 2017 and was the co-organiser of the inaugural Drug Discovery Conference on CNS Malignancies in 2014. He has served on the Chemists in Cancer Research Steering Committee for the American Association of Cancer Research (AACR).

Prior to his time at Genentech, Dr. Olivero was at Henkel Research Corporation/Cognis, Inc. where he started up a business unit in bio-catalysis. He has co-authored numerous scientific publications and is a named inventor on over 40 patents. Dr. Olivero currently lives in the San Francisco Bay Area and consults for multiple biotechnology and pharma companies, including his former employer Genentech.

quote-icon

"I think a lot of neuro-oncologists are still looking at their patients and trying to give them hope... [However] there's a lot of people out there who tell you all the ways you can fail, I'm not really impressed by them."

Dr Alan Olivero, PhD
Read more

Prof Patrick Wen, MD

Professor of Neurology
Harvard Medical School

Director of the Center for Neuro-Oncology
Dana-Faber Cancer Institute, Boston

Watch Patrick's video
close

Prof Patrick Wen, MD

Professor of Neurology
Harvard Medical School

Director of the Center for Neuro-Oncology
Dana-Faber Cancer Institute, Boston

Director at the Division of Neuro-Oncology
Brigham and Women’s Hospital

Executive Committee Member
Response Assessment in Neuro-Oncology (RANO) working group

Watch Patrick's video

Prof Patrick Wen is Professor of Neurology at Harvard Medical School, and Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute in Boston, MA. His research focuses on novel treatments of brain tumours, especially targeted molecular agents with an understanding that brain tumours are heterogenous, which to date, is yet to be fully addressed.

Dr Wen graduated from the Medical College of St. Bartholomew's Hospital at the University of London. After this he completed his Internal Medicine training at the University of London postgraduate hospitals, and later his Neurology residency through the Harvard-Longwood Neurology Training Program.

Dr Wen is a Professor of Neurology at Harvard Medical School, Director at the Center for Neuro-Oncology at the Dana-Farber Cancer Institute, as well as Director at the Division of Neuro-Oncology at the Brigham and Women’s Hospital.

The primary goal of Dr Wen’s multidisciplinary group of investigators is to identify more effective treatments for brain cancer sufferers. He is particularly interested in the development of novel targeted molecular therapies. With his colleagues, he has established a large number of clinical trials utilising these agents.

More recently his team have developed trials using a combination of targeted molecular agents, which they hope will be more effective than single agents alone. Of note, they are also genotyping tumours and correlating them with response to treatment, enabling better identification of sub-groups of patients that are more likely to benefit.

Dr Wen is a principal investigator of the Adult Brain Tumour Consortium, member of the Executive Committee of the Response Assessment in Neuro-Oncology (RANO) working group, and he is the immediate past President of the Society of Neuro-Oncology, former Editor-In-Chief of Neuro-Oncology, and currently the Society of Neuro-Oncology Executive Editor of Neuro-Oncology.

Dr Wen has authored more than 700 of peer-reviewed articles published in leading international journals. These include Neuro-Oncology, Neurology, Current Opinion in Neurology, and Journal of Clinical Oncology.

quote-icon

“I think we know in glioblastomas that there is tremendous heterogeneity within different areas of the tumour, and there is temporal heterogeneity as well. The hope is that with vaccines there may be epitope spread and that the immune system can adapt to the development of new antigens and that may have an advantage over targeted therapies."

Prof Patrick Wen, MD
Read more

Prof John de Groot, MD

Professor and Chief of Neuro-Oncology
University of California, San Francisco

Watch John's video
close

Prof John de Groot, MD

Professor and Chief of Neuro-Oncology
University of California, San Francisco

Watch John's video

Dr John de Groot is Chief of Neuro-Oncology at University of California, San Francisco and previous Director of Clinical Research in Neuro-Oncology and Interim Chair of the Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center. He has extensive expertise in the fields of clinical and translational research in the fields of glioma angiogenesis, molecularly targeted therapy, and immunotherapy. His broad clinical and laboratory experience has given him a unique perspective on the translation of novel therapies into the clinic for the treatment of patients with primary brain tumours.

Dr John de Groot is a Professor in the Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center. He has extensive expertise in the fields of clinical and translational research in the fields of glioma angiogenesis, molecularly targeted therapy, and immunotherapy. His broad clinical and laboratory experience has given him a unique perspective on the translation of novel therapies into the clinic for the treatment of patients with primary brain tumours.

Dr de Groot studied medicine at The University of Texas Medical Branch at Galveston and pursued internship and residency at Johns Hopkins School of Medicine. Following a clinical fellowship at MD Anderson, Dr de Groot joined the faculty in 2004, and his contribution to the brain cancer landscape has increased ever since.

His translational research program has produced critical insights into how gliomas respond to and resist being killed by anti-angiogenic agents and identified therapeutic approaches that have been implemented in clinical trials to overcome resistance by the tumour. Dr de Groot has also contributed to the discovery of biomarkers of response and progression in glioblastoma sufferers treated with anti-angiogenic agents, and as such developed multiple biomarker-driven clinical trials that are biomarker-driven.

Dr de Groot has received funding from multiple National Cancer Institute, foundation, and industry-sponsored grants. He is involved in a number of clinical trials utilising novel agents in glioblastoma sufferers and is a co-leader of the MD Anderson GBM Moon Shot program. Dr de Groot has over 140 peer-reviewed articles in leading international journals and has peer-reviewed for 23 scientific journals. In addition, Dr de Groot is the director of the Neuro-Oncology Fellowship Program, engaging and directing the teachings of the next generation of clinician-scientists.

quote-icon

"I am incredibly honoured to join the Scientific Advisory Committee for the Cure Brain Cancer Foundation, the leading organization for brain cancer research, advocacy and awareness in Australia. Working together with the visionary leadership at CBCF, I am committed to advancing the best research opportunities for patients with brain cancer."

Prof John de Groot, MD
Read more

Prof Angel Lopez, PhD, MD, AO

Recent past Founding Co-Director
Center for Cancer Biology, South Australia

Co-founder
South Australian Immunogenomics Cancer Institute

Watch Angel's video
close

Prof Angel Lopez, PhD, MD, AO

Recent past Founding Co-Director
Center for Cancer Biology, South Australia

Co-founder
South Australian Immunogenomics Cancer Institute

Watch Angel's video

Professor Angel Lopez is the recent past Co-Director of the Center of Cancer Biology in Australia. He currently is the Head of Division of Human Immunology at SA Pathology where his research team works on developing new treatments for eliminating leukaemia stem cells and continues to examine the mechanisms of cytokine actions in cancer.

Professor Angel Lopez received his medical degree in 1975 from the University of Rosario, Argentina, and his PhD from the University of London in 1981. He conducted his post-doctoral work at the Walter and Eliza Hall Institute and has since been the author of more than 240 research publications. Professor Angel’s research continues to lead to new understandings of cytokine receptor signalling which has underpinned the development of new therapeutics with the potential to change clinical practice.

He has worked for over 30 years on the structure and function of cytokine receptors and their mechanism of action in health and disease. The work of his laboratory has been highly collaborative involving several academic and clinical groups. The long-standing collaboration with Professor Michael Parker’s group (St. Vincent’s Institute of Medical Research and Bio21 Institute) has been a continuous source of enjoyment and successes that revealed significant new paradigms in cytokine receptor activation that were published in major international journals.

Similarly, the collaboration with CSL Ltd over many years has enabled the practical application of the laboratory’s insights and the development of several anti-receptor antibodies into potential new treatments for acute myeloid leukaemia and for allergic inflammatory conditions. Prof Lopez is a co-founder of the South Australian Immunogenomics Cancer Institute (SAiGENCI) (established 2020) thanks to an $80M grant from the Commonwealth Government.

Prof Lopez was elected a Fellow of the Australian Academy of Science in 2014 and in 2015 was elected a Fellow of the Australian Academy of Health and Medical Sciences. He was an inaugural convenor of the biennial “Barossa Signalling Meetings”, now coming on to its tenth edition. Prof Lopez received the 2010 South Australian Scientist of the Year Award and the 2010 South Australian of the Year - Science Category Award from the SA Government. In June 2017 he was made an Officer to the Order of Australia (AO) for his medical and scientific research in the areas of immunology, cell biology and innovative developments in cancer treatment.

quote-icon

“People are always asking me ‘where’s the cure for cancer?’ The good news is that, as researchers, we are curing more cancers. That’s what drives us."

Prof Angel Lopez, PhD, MD
Read more

Prof Mark Rosenthal, PhD, MD

Senior Staff Specialist in the Department of Medical Oncology
Peter MacCallum Cancer Centre

Director
Parkville Cancer Clinical Trials Unit

Watch Mark's video
close

Prof Mark Rosenthal, PhD, MD

Senior Staff Specialist in the Department of Medical Oncology
Peter MacCallum Cancer Centre

Director
Parkville Cancer Clinical Trials Unit

Watch Mark's video

Professor Mark Rosenthal trained as a Medical Oncologist in Melbourne and Sydney, Australia and received a Doctorate of Philosophy for a thesis examining the molecular genetics of colon cancer conducted at the Ludwig Institute for Cancer Research (1992-1996). He completed post-graduate training at New York University Medical Centre, New York, USA (1996-98) was a Senior Staff Specialist in the Department of Medical Oncology, Royal Melbourne Hospital (1998-2016) and Professor Director of the Department from 2006-2016. He was Chair and Chief Medical Officer of Cancer Trials Australia (2006-2016), inaugural Chair of the Cooperative Trials Group for Neuro-Oncology (2007-2017) and was the Clinical Trials Lead for the Victorian Comprehensive Cancer Centre (2016-20)

Professor Rosenthal is currently a Senior Staff Specialist in the Department of Medical Oncology at the Peter MacCallum Cancer Centre and Director of the Parkville Cancer Clinical Trials Unit. He has published over 160 peer-reviewed manuscripts and has been awarded over $17 million in competitive research grants. His major interests include neuro-oncology and early phase clinical trials.

quote-icon

“Cure Brain Cancer Foundation has had a genuine impact on brain cancer research and the care of Australian’s with brain cancer. I’m thrilled to be part of a Team that will drive the next iteration of research; always with the aim of improving care.”

Prof Mark Rosenthal, PhD, MD
Read more

Dr Natasha Monin (BSc, MBBS)

Global Medical Affairs Partner in Neurology and Rare Diseases
UCB Biopharma

Watch Natasha's video
close

Dr Natasha Monin (BSc, MBBS)

Global Medical Affairs Partner in Neurology and Rare Diseases
UCB Biopharma

Watch Natasha's video

Dr Natasha Monin (BSc, MBBS), is a Global Medical Affairs Partner in Neurology and Rare Diseases at UCB Biopharma and responsible for developing learning interventions for physicians across a number of neurologic conditions. Her major interests include Rare Neurologic Diseases, Movement Disorders and early clinical development programs.

Dr Monin is a trained General Medicine Doctor with over 28+ years’ experience across the biopharmaceutical and healthcare industries, in both international and domestic markets including Japan, South Korea, India, Taiwan, Hong Kong, New Zealand (Asia Pacific) and Australia. She has spent the last 12 years as a local and regional (APAC) Medical Director.

Additionally, in a pro bono capacity, she serves as a mentor for an Australian biotechnology start-up company.

quote-icon

"I am looking forward to contributing to improving quality of life of patients and families touched by the devastation of brain cancer, so that in the future, patients and their families have more treatment options available to them in Australia."

Dr Natasha Monin (BSc, MBBS)
Read more

Dr Helen Wheeler

Head of Medical Oncology
Royal North Shore and Head of the Medical Oncology clinical trials unit

Watch Helen's video
close

Dr Helen Wheeler

Head of Medical Oncology
Royal North Shore and Head of the Medical Oncology clinical trials unit

Watch Helen's video

Dr Helen Wheeler trained as a Medical Oncologist in Sydney Australia. After finishing her medical training she spent three years in benchtop research in cancer immunology under the supervision of Prof Caroyln Geczy at The Kolling Institute, before taking up a full time position as a staff specialist at Royal North Shore Hospital, St Leonards, Sydney.

Her early oncology career involved management of many different solid tumours, but gradually became more focused on primary brain cancer. Although much of her time is spent on clinical work, she has always been involved in clinical trials and translational cancer research.

She is currently Head of Medical Oncology at Royal North Shore and Head of the Medical Oncology clinical trials unit which conducts trials ranging from phase 1 to phase 3 randomised trials as well as clinical translational projects.

She continues to collaborate with the Bill Walsh Cancer laboratory, which has a number of benchtop research projects in brain cancer.

quote-icon

“There is still so much unknown about the cause of brain cancer and treatment remains very limited. Little has changed in the past 20 years. Cure Brain Cancer raises funds that allow this research to continue and gain momentum, giving hope that new treatment will become available in the not too distant future.”

Dr Helen Wheeler
Read more
back-to-top